Oct 11, 2008 PXE News
October 11, 2008
5th Annual North American ABC Meeting
A key session at the ABC meeting, titled "Pseudoxanthoma elasticum, ABCC6, and Vitamin K?", generated vigorous discussion, and PXE International is pursuing new leads.
October 11, 2008
5th Annual North American ABC Meeting
A key session at the ABC meeting, titled "Pseudoxanthoma elasticum, ABCC6, and Vitamin K?", generated vigorous discussion, and PXE International is pursuing new leads.
October 1, 2010
PXE International BioBank and Clinical Data Registry
What disease has the world's largest rare disease biobank and repository? Pseudoxanthoma elasticum (PXE)! How can you be involved? What has it done for you lately?
October 7, 2010
The ABCC6 (MRP6) Gene and Gene Patenting
PXE International, a non-profit research foundation, is the owner of the intellectual property rights in the form of multiple worldwide patents issued for the diagnostic and therapeutic use of the gene associated with PXE, ABCC6. What does being the patent holder mean?
October 12, 2011
Lay Summary: The Effects of Pseudoxanthoma Elasticum (PXE) on the Placenta and Pregnancy
Early literature on pregnancy in women with pseudoxanthoma elasticum [PXE] contained reports of severe complications. However, more recent studies do not support that recommendation and to date, there is no strong evidence linking PXE to complications during pregnancy for the mother or the fetus.
October 28, 2011
Rescue of ABCC6 Disease-Causing Mutations in Mouse Liver
In a very complex experiment, a team of PXE researchers led by Dr. Váradi and Dr. Le Saux were able to rescue some function in an ABCC6 gene with disease-causing mutations in a live mouse liver. This news is very exciting and may have some application to a future therapy for pseudoxanthoma elasticum in humans.
October 23, 2012
9th Annual North American ABC Meeting, Frederick, MD, September 27-28, 2012
The 9th Annual North American ABC Meeting held last month at the National Cancer Institute in Frederick, MD featured presentations from scientists studying the role of ATP-binding cassette proteins in human disease.
Avastin and Lucentis are Equivalent in Treating AMD: CATT Two-Year Results
In July 2012, Ophthalmology published the final results from the two-year Comparison of Age-related Macular Degeneration Treatments Trials (CATT) clinical trial comparing Lucentis and Avastin treatments for wet age-related macular degeneration (AMD).